4.8 Article

The type I TGF-β receptor is covalently modified and regulated by sumoylation

Journal

NATURE CELL BIOLOGY
Volume 10, Issue 6, Pages 654-664

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/ncb1728

Keywords

-

Categories

Funding

  1. NCI NIH HHS [R01 CA116019-03, R21-CA125190, R01 CA063101, R21 CA125190, R21 CA125190-01, R01 CA116019, R01-CA63101, R21 CA125190-02] Funding Source: Medline
  2. NHLBI NIH HHS [R01 HL078564] Funding Source: Medline
  3. NIAMS NIH HHS [P01 AR050440] Funding Source: Medline

Ask authors/readers for more resources

Post- translational sumoylation, the covalent attachment of a small ubiquitin-like modifier (SUMO), regulates the functions of proteins engaged in diverse processes. Often associated with nuclear and perinuclear proteins, such as transcription factors, it is not known whether SUMO can conjugate to cell-surface receptors for growth factors to regulate their functions. Here we show that the type I transforming growth factor-beta (TGF-beta) receptor, T beta RI, is sumoylated in response to TGF-beta and that its sumoylation requires the kinase activities of both T beta RI and the type II TGF-beta receptor, T beta RII. Sumoylation of T beta RI enhances receptor function by facilitating the recruitment and phosphorylation of Smad3, consequently regulating TGF-beta-induced transcription and growth inhibition. T beta RI sumoylation modulates the dissemination of transformed cells in a mouse model of T beta RI-stimulated metastasis. T beta RI sumoylation therefore controls responsiveness to TGF-beta, with implications for tumour progression. Sumoylation of cell-surface receptors may regulate other growth factor responses.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available